Twice daily versus once nightly dosing of pregabalin for fibromyalgia: A double-blind randomized clinical trial of efficacy and safety

Arthritis Care and Research

Volumn 66, Issue 2, 2014, Pages 293-300

  Nasser, Keaton ^a   Kivitz, Alan J ^b   Maricic, Michael J ^c   Silver, David S ^a,d   Silverman, Stuart L ^a,d,e  

^a Osteoporosis Medical Center   (United States)

^b Altoona Clinical Research   (United States)

^c Catalina Pointe Rheumatology   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANALGESIA; ARTICLE; BLURRED VISION; CONTROLLED STUDY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EVENING DOSAGE; FATIGUE; FEMALE; FIBROMYALGIA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; LOGISTIC MODELS; MIDDLE AGED; PAIN MEASUREMENT; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84893364332     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22111     Document Type: Article

References (18)

1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L,. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
2. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58: 26-35.
3. Wolfe F, Brahler E, Hinz A, Hauser W,. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken) 2013; 65: 777-85.
4. McNally JD, Matheson DA, Bakowsky VS,. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 2006; 27: 9-16.
5. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
6. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62: 600-10.
7. Richards S, Cleare A,. Treating fibromyalgia. Rheumatology (Oxford) 2000; 39: 343-6.
8. Barkhuizen A,. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002; 28: 261-90.
9. Straube S, Derry S, Moore RA, McQuay HJ,. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010; 49: 706-15.
10. Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC,. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain 2008; 9: 1006-17.
11. Serra E,. Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia? Nat Clin Pract Neurol 2008; 4: 594-5.
12. Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM,. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken) 2012; 64: 597-606.
13. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL,. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009; 11: R120.
14. Okifuji A, Turk DC, Sinclair JD, Starz TW, Marcus DA,. A standardized manual tender point survey I: development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 1997; 24: 377-83.
15. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM,. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-58.
16. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB,. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009; 36: 1304-11.
17. Kim SM, Lee SH, Kim HR,. Applying the ACR preliminary diagnostic criteria in the diagnosis and assessment of fibromyalgia. Korean J Pain 2012; 25: 173-82.
18. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011; 38: 1113-22.